XML 66 R53.htm IDEA: XBRL DOCUMENT v3.19.1
License agreements - Agenus (Details)
$ / shares in Units, $ in Thousands, shares in Millions
1 Months Ended 3 Months Ended
Feb. 14, 2017
USD ($)
$ / shares
Feb. 01, 2017
USD ($)
$ / shares
shares
Feb. 28, 2017
USD ($)
Nov. 30, 2015
item
Feb. 28, 2015
Jan. 31, 2015
item
Mar. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Mar. 31, 2018
USD ($)
Mar. 31, 2017
USD ($)
Sep. 30, 2018
USD ($)
Jun. 30, 2018
USD ($)
License agreements                        
Long term investment             $ 120,188 $ 99,199 [1]        
Research and development expense             270,545   $ 303,103      
Unrealized gain (loss) on long term investments             20,989   22,679      
Current assets             1,904,500 1,832,254 [1]        
Current liabilities             364,515 425,277 [1]        
Cash and cash equivalents             $ 1,299,704 1,163,980 [1]        
Agenus                        
License agreements                        
Number of program targets | item       3   4            
Royalty payments on future global net sales (as a percent)             15.00%          
Period of notice for termination of license agreement     12 months                  
Agenus | Development, Regulatory and Commercialization Milestones | Minimum                        
License agreements                        
Royalty payments on future global net sales (as a percent)             6.00%          
Agenus | Development, Regulatory and Commercialization Milestones | Maximum                        
License agreements                        
Royalty payments on future global net sales (as a percent)             12.00%          
Additional milestone payments under the license agreement     $ 510,000                  
Agenus | Development Milestones                        
License agreements                        
Upfront payment under license agreement     $ 20,000                  
Additional milestone payments under the license agreement                     $ 5,000 $ 5,000
Agenus                        
License agreements                        
Long term investment             $ 52,600 42,300        
Research and development expense             $ 10,200   1,900      
Shares owned following stock purchase (as a percent)     11.00%   9.00%              
Ownership percentage (as a percent)             13.00%          
Unrealized gain (loss) on long term investments             $ 10,500   $ 25,800      
Total revenues               6,500        
Net income (loss)               48,800        
Agenus | Accrued and other liabilities                        
License agreements                        
Accrued and other liabilities             $ 4,700 $ 2,300        
Agenus | Stock purchase agreement                        
License agreements                        
Purchase of common stock under Stock Purchase Agreement (in shares ) | shares   10.0                    
Purchase price of common stock   $ 60,000                    
Per share price | $ / shares $ 4.40 $ 6.00                    
Discount for lack of marketability $ 4,500                      
Fair value of shares on the issuance date 39,500                      
Total consideration paid $ 60,000                      
Long term investment                   $ 39,500    
Research and development expense                   $ 20,500    
[1] The condensed consolidated balance sheet at December 31, 2018 has been derived from the audited financial statements at that date.